Sideras, K., Ingle, J.N., Ames, M.M., Loprinzi, C.L., Mrazek, D.P., Black, J.L., Weinshilboum, R.M., Hawse, J.R., Spelsberg, T.C
While some would consider that figure to be jaw-dropping, it could have been a lot higher had it not been for the ongoing drug shortage, which has had a significant impact on the GLP-1 market
A study published in 2025 regarding predictors of return to work after thyroid surgery found that nearly 80 percent of patients returned to work successfully
This dual action assists in weight management and aids in the better management of type 2 diabetes, making it a versatile tool in treating obesity and diabetes-related conditions
There are three GLP-1 FDA decisions expected in 2025, all for Novo Nordisks semaglutide: Ozempic for T2DM and peripheral artery disease (PAD) Wegovy SC for heart failure with preserved ejection fraction (HFpEF) and obesity The first oral GLP-1 ( oral formulation of Wegovy 25 mg ) for weight loss and weight loss plus secondary CV risk reduction Given the considerable continued growth expected in the GLP-1 pipeline, Prime Therapeutics talented team of clinical experts actively monitors this emerging landscape
